Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.
Recent comments
9 weeks 1 day ago
10 weeks 20 hours ago
11 weeks 4 days ago
12 weeks 1 day ago
12 weeks 3 days ago
16 weeks 6 days ago
17 weeks 6 days ago
18 weeks 7 hours ago
19 weeks 2 days ago
24 weeks 3 days ago